Drug · DIN 02547465
APRETUDE
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since June 19, 2024; first marketed June 19, 2024.
- Drug Identification Number (DIN)
- 02547465
- Company (DIN owner)
- Viiv Healthcare UlcMontreal, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Cabotegravir J05AJ04
- Class
- Human
- Record last updated
- September 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| CABOTEGRAVIR (CABOTEGRAVIR SODIUM) | 30 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- May 13, 2024: NOC 33204New Drug Submission (NDS)
Other DINs named APRETUDE
- DIN 02547473 · Marketed